Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported fiscal 2024 results in line with January’s preannouncement, and management remains optimistic on the potential for bringing in value-add, late-stage assets in the infectious disease space as the best way to maximize the value of its hepatitis B vaccine, HEPLISAV-B, the analyst tells investors in a research note. Management also continues to seek out assets in the infectious disease space, and believes there are viable assets, the firm notes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVAX:
- Dynavax: Undervalued Stock with Strong Growth Potential and Market Expansion Plans
- Dynavax Technologies Reports Strong Growth in 2024
- Dynavax reports Q4 EPS 5c, two estimates 4c
- Dynavax sees FY25 adjusted EBITDA ‘at least $75M’ vs. $51.9M in FY24
- DVAX Earnings this Week: How Will it Perform?